NeuroPace today released 7-year follow-up data from a clinical trial of its RNS neurostimulation system designed to prevent epileptic seizures, touting an over-70% reduction in seizure frequency.
The company’s RNS system is a closed-loop brain-responsive neurostim system designed for preventing epileptic seizures, and has been approved by the FDA as adjunctive therapy to treat partial onset epilepsy in patients who are non-responsive to medication.
Data from the study was presented this week at the American Epilepsy Society’s meeting in Houston, the Mountain View, Calif.-based company said.
Follow-up data indicated a median reduction in seizure frequency of 72% at 7 years. At 7-years, 25% of patients reported a seizure reduction of greater than or equal to 93% for any 3 month period in the year, the company said.
A total 29% of patients in the trial reported experiencing 1 or more 6-month period free from seizures, according to a press release.
Clinical trial patients are continuing to be treated in an ongoing long-term treatment study, NeuroPace said, which is an ongoing, multi-center prospective open-label study for participants in either a feasibility or randomized controlled trial of the RNS system.
